<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395339</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-012</org_study_id>
    <nct_id>NCT04395339</nct_id>
  </id_info>
  <brief_title>GM1 Prophylaxis for WBRT Related Cognitive Dysfunction</brief_title>
  <acronym>GLORY</acronym>
  <official_title>Ganglioside-Monosialic Acid Prophylaxis for Cognitive Dysfunction Related to Whole Brain Radiotherapy in Breast Cancer Patients With Brain Metastases ，a Multi-center，Randomized，Single Blind，Phase III Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of GM1 for preventing cognitive impairment related to&#xD;
      whole brain radiotherapy in breast cancer patients with brain metastases. And explore the&#xD;
      clinical and molecular parameter for predicting severe cognitive impairment induced by WBRT&#xD;
      and gaining benefit from GM1.&#xD;
&#xD;
      Primary Endpoint: the change of Hopkins Verbal and Learning Test-Revised Delayed&#xD;
      Recall,HVLT-R DR,before and after WBRT Secondary ENDPOINT: the change of Alzheimer's Disease&#xD;
      Assessment Scale-Cognitive，ADAS-Cog before and after WBRT;severe cognitive impairment&#xD;
      percentage and onset time; Design:204 patients will be randomly assigned to exp.group,102&#xD;
      cases,and 102 cases of control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:Brain metastasis is a common event for advanced stage cancer,and whole brain&#xD;
      radiotherapy(WBRT)is one of the most effective and widely utilized measures for brain&#xD;
      metastases.Gaining control of the brain metastases may provide better survival for&#xD;
      patients,but can also cause cognitive impairment,sometimes may be severe.Considering&#xD;
      cognitive function is one of the most important aspect of quality of life(QoL), some remedies&#xD;
      for the treatment-related adverse effect should be provided. Some agents were evaluated for&#xD;
      this purpose,and results were unsatisfying. Ganglioside-Monosialic Acid (GM1) is used as an&#xD;
      neuroprotective agent after brain surgery or neurodegenerative disease,and a clinical&#xD;
      trail(NCT02468739) hosted by our team demonstrated that it could relief taxane-induced&#xD;
      neurotoxicity.So GM1 is proposedto be effective in treating WBRT related cognitive&#xD;
      dysfunction.&#xD;
&#xD;
      Outline:This will be an single-blind,randomized study,102 patients planning to receive WBRT&#xD;
      will be allocated to control and experiment group,respectively,to receive GM1(100mg D0-D14)&#xD;
      or placebo(0.9% saline).Cognitive scales will be utilized to evaluate the efficacy.&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      Evaluate the efficacy of GM1 in alleviating WBRT related cognitive impairment by Hopkins&#xD;
      Verbal and Learning Test Revised-Delayed Recall(HVLT-R DR) before and after RT.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      Evaluate the efficacy of GM1 in alleviating WBRT related cognitive impairment by Alzheimer's&#xD;
      Disease Assessment Scale-Cognitive(ADAS-Cog )before and after RT.&#xD;
&#xD;
      Evaluate the efficacy of GM1 in alleviating WBRT related cognitive impairment by Mini-mental&#xD;
      state Examination(MMSE)before and after RT.&#xD;
&#xD;
      Evaluate the efficacy of GM1 in alleviating WBRT related cognitive impairment by comparing&#xD;
      severe cognitive impairment incidence,and onset time of cognitive dysfunction.&#xD;
&#xD;
      Explore the molecular parameter for GM1 benefit. Treatment group: Ganglioside-Monosialic Acid&#xD;
      is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via&#xD;
      intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of&#xD;
      the radiotherapy. At the same time, the patients are treated with a WBRT protocol selected by&#xD;
      the investigators.&#xD;
&#xD;
      Placebo group: Placebo is 250 mL of 0.9% sodium chloride injection, which is given once a day&#xD;
      via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start&#xD;
      of the RT. At the same time, the patients are treated with a WBRT protocol selected by the&#xD;
      investigators.&#xD;
&#xD;
      Follow up: Assessment will be performed before and 12,24 36,48 weeks after RT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HVLT R-DR</measure>
    <time_frame>24 weeks after WBRT.</time_frame>
    <description>The change of score for Hopkins verbal learning test -revised,delayed recall,form baseline to 24weeks after WBRT,score ranges from 0 to 12,higher score indicates better cognitive function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADAS-Cog</measure>
    <time_frame>24 weeks after WBRT.</time_frame>
    <description>The change of score for Alzheimer's Disease Assessment Scale-Cognitive，ADAS-Cog,form baseline to 24 weeks after WBRT,score ranges from 0 to 75,LOWER score indicates better cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>24 weeks after RT.</time_frame>
    <description>The change of score for Minimal Mental State Examination,MMSE,form baseline to 24 weeks after WBRT,higher score indicates better cognitive function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Gangliosidosis, GM1</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm(GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be treated with GM1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will be treat with blank placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monosialotetrahexosyl ganglioside (GM1)</intervention_name>
    <description>Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.</description>
    <arm_group_label>Experimental arm(GM1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-75,with histological affirmative breast cancer ,and over 4 brain&#xD;
             metastases ,need for WBRT suggested by radiotherapy oncologist ;&#xD;
&#xD;
          -  Estimated survival time over 6months;&#xD;
&#xD;
          -  Abundant hematological function:Absolute Neutrophil Count≥2×109/L ;platelet&#xD;
             count≥100×109/L and hemoglobulin≥9 g/dL;&#xD;
&#xD;
          -  Abundant liver function：total bilrubin≤ULN；ASTandALT≤2.5ULN；AKP≤5ULN&#xD;
&#xD;
          -  Can cope with HVLT-RDR and ADAS-Cog evaluation&#xD;
&#xD;
          -  No prior therapy could induce neurological damage,within 4 weeks&#xD;
&#xD;
          -  No more that 1 degree peripheral neuropathy or any other diseases or symptoms that&#xD;
             could hinder the evaluation of neurological AE&#xD;
&#xD;
          -  No more treatment or nursing is allowed after enrolling this trail&#xD;
&#xD;
          -  Written Informed Consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PS score over 2,and estimated no attenuation by WBRT&#xD;
&#xD;
          -  Women with pregnancy or breast feeding&#xD;
&#xD;
          -  Unwilling to contraception measurement&#xD;
&#xD;
          -  Abnormal baseline impairment of cognitive impairment&#xD;
&#xD;
          -  Allergy to experiment agents or components&#xD;
&#xD;
          -  Unsuitable to GM1 treatment, evaluated by investigators&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  RT dose over 30Gy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiajia Huang, MD,PhD</last_name>
    <phone>+86 02087343794</phone>
    <email>huangjiaj@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongyi Zhong, BD</last_name>
    <phone>+86 02087343794</phone>
    <email>ZHONGYY@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhongyu yuan, MD,PhD</last_name>
      <email>YUANZHY@SYSUCC.ORG.CN</email>
    </contact>
    <contact_backup>
      <last_name>yongyi zhong, BD</last_name>
      <email>zhongyy@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhenyu he, MD,Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiajia Huang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>WBRT</keyword>
  <keyword>Gangliosidoses</keyword>
  <keyword>Brain Metastases</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Gangliosidoses</mesh_term>
    <mesh_term>Gangliosidosis, GM1</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

